Mechanistic and therapeutic relationships of traumatic brain injury and γ-amino-butyric acid (GABA)

Witkin, Jeffrey M.; Shafique, Hana; Cerne, Rok; Smith, Jodi L.; Marini, Ann M.; Lipsky, Robert H.; Delery, Elizabeth

doi:10.1016/j.pharmthera.2024.108609

Cited by 1 publication

(1 citation statement)

References 239 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glutamatergic neurotransmission is responsible for many cognitive, motor, sensory, and autonomic nervous activities [ 220 , 221 , 222 ]. Neuroexcitotoxicity induced by glutamate has been demonstrated in a number of neurological and psychiatric disorders, including PD [ 223 , 224 , 225 , 226 , 227 ], epilepsy [ 228 , 229 ], traumatic brain injury [ 230 , 231 ], MS [ 232 , 233 , 234 ], AD [ 223 , 224 , 235 , 236 ], HD [ 223 , 237 , 238 , 239 ], ALS [ 223 , 239 , 240 ], etc.…”

Section: Resultsmentioning

confidence: 99%

L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review

Wang,

Pan,

Liu

et al. 2024

Nutrients

View full text Add to dashboard Cite

L-carnitine (LC), a vital nutritional supplement, plays a crucial role in myocardial health and exhibits significant cardioprotective effects. LC, being the principal constituent of clinical-grade supplements, finds extensive application in the recovery and treatment of diverse cardiovascular and cerebrovascular disorders. However, controversies persist regarding the utilization of LC in nervous system diseases, with varying effects observed across numerous mental and neurological disorders. This article primarily aims to gather and analyze database information to comprehensively summarize the therapeutic potential of LC in patients suffering from nervous system diseases while providing valuable references for further research. Methods: A comprehensive search was conducted in PubMed, Web Of Science, Embase, Ovid Medline, Cochrane Library and Clinicaltrials.gov databases. The literature pertaining to the impact of LC supplementation on neurological or psychiatric disorders in patients was reviewed up until November 2023. No language or temporal restrictions were imposed on the search. Results: A total of 1479 articles were retrieved, and after the removal of duplicates through both automated and manual exclusion processes, 962 articles remained. Subsequently, a meticulous re-screening led to the identification of 60 relevant articles. Among these, there were 12 publications focusing on hepatic encephalopathy (HE), while neurodegenerative diseases (NDs) and peripheral nervous system diseases (PNSDs) were represented by 9 and 6 articles, respectively. Additionally, stroke was addressed in five publications, whereas Raynaud’s syndrome (RS) and cognitive disorder (CD) each had three dedicated studies. Furthermore, migraine, depression, and amyotrophic lateral sclerosis (ALS) each accounted for two publications. Lastly, one article was found for other symptoms under investigation. Conclusion: In summary, LC has demonstrated favorable therapeutic effects in the management of HE, Alzheimer’s disease (AD), carpal tunnel syndrome (CTS), CD, migraine, neurofibromatosis (NF), PNSDs, RS, and stroke. However, its efficacy appears to be relatively limited in conditions such as ALS, ataxia, attention deficit hyperactivity disorder (ADHD), depression, chronic fatigue syndrome (CFS), Down syndrome (DS), and sciatica.

show abstract